The effects of cannabinoid receptor antagonists against neuroprotective effects of compound 4f in KA-treated mice. by Naoto Arimura (416442)

Subjects:

Representative image data in Fig 5. by Naoto Arimura (416442)

Subjects:

Pharmacokinetics and pharmacodynamics of compound 4f in mice. by Naoto Arimura (416442)

Subjects:

The raw data for S2 Fig. by Hongjoo An (21703199)

Subjects:

The raw data for Fig 5B. by Hongjoo An (21703199)

Subjects:

Effects of compound 4f on cognitive function in mice with KA-induced neurodegeneration. by Naoto Arimura (416442)

Subjects:

The raw data for Fig 8A. by Hongjoo An (21703199)

Subjects:

Effects of compound 4f on neuronal cell loss in mice with KA-induced neurodegeneration. by Naoto Arimura (416442)

Subjects:

The raw data for Fig 6. by Hongjoo An (21703199)

Subjects:

The raw data for S4 Fig. by Hongjoo An (21703199)

Subjects:

Comparison of altered gene expression across groups of saline/vehicle-, KA/vehicle-, and KA/compound 4f-treated mice. by Naoto Arimura (416442)

Subjects:

Effects of compound 4f on the seizure-like response elicited by kainic acid (KA). by Naoto Arimura (416442)

Subjects:

Recruitment flow diagram of the current study. by Somayeh Momenyan (10111603)

“…Phase 1 EQ-VAS decreases were associated with female sex, lower somatic symptom, fewer comorbidities, lack of expectation for a fast recovery, higher ISS, higher injury pain, neck, spine/back or lower extremity injuries. …”

Stratified <i>Giardia</i> infection prevalence rates in nonhuman mammalian hosts based on ecological and biological characteristics. by Kareem Hatam-Nahavandi (7384790)

Subjects:

<i>hdc</i> silencing results in cellular stress in the hematopoietic niche. by Bayan Kharrat (19959505)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”